The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2): Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.
 
Michael Thomas Mark
Consulting or Advisory Role - AstraZeneca; bms; MSD Oncology; Roche; Takeda
Research Funding - Gilead Sciences (Inst); Swiss Cancer Research Foundation (Inst)
Travel, Accommodations, Expenses - Merck (Inst); Roche (Inst); Takeda (Inst)
 
Patrizia Froesch
Consulting or Advisory Role - Janssen Oncology; Lilly; Novartis; Pfizer; Roche; Sanofi; Takeda
 
Katrin Gysel
No Relationships to Disclose
 
Sacha Rothschild
Honoraria - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Otsuka (Inst); Pfizer (Inst); PharmaMar (Inst); Roche Pharma AG (Inst); Sanofi (Inst); Takeda (Inst)
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Otsuka (Inst); Pfizer (Inst); Roche Pharma AG (Inst); Takeda (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Roche Pharma AG (Inst); Sanofi; Takeda (Inst)
Other Relationship - Federal Drug Commission of the Swiss Federal Office of Public Health; Swiss Group for Clinical Cancer Research (SAKK) (Inst)
 
Alfredo Addeo
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bristol Myers Squibb Foundation; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca/MedImmune; Lilly
Travel, Accommodations, Expenses - Roche; Takeda
 
Christoph J. Ackermann
Travel, Accommodations, Expenses - travel and accomodation expenses (Inst)
 
Sabrina Chiquet
No Relationships to Disclose
 
Martina Schneider
No Relationships to Disclose
 
Karin Ribi
No Relationships to Disclose
 
Angela Fischer Maranta
Consulting or Advisory Role - MSD Oncology (Inst)
Travel, Accommodations, Expenses - Janssen Oncology (Inst)
 
Sara Bastian
Consulting or Advisory Role - AstraZeneca (Inst); BMSi (Inst); MSD Oncology (Inst)
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
Roger Anton Fredy Von Moos
Consulting or Advisory Role - Gilead Sciences; GlaxoSmithKline; Lilly O.; Merck; MSD Oncology; PharmaMar; Pierre Fabre; Sanofi; Vifor Pharma
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Pierre Fabre; Takeda
 
Markus Joerger
Consulting or Advisory Role - AstraZeneca (Inst); Basilea Pharmaceutical (Inst); Bristol-Myers Squibb (Inst); Innomedica (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Immunophotonics (Inst); Innomedica (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
 
Martin Früh
Consulting or Advisory Role - AstraZeneca (Inst); BMSi (Inst); Boehringer Ingelheim (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
Research Funding - AstraZeneca (Inst); MSD (Inst)